BioSpace News Archive

Avidity Biosciences, Inc. announced that on May 20, 2024, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 150,500 shares of its common stock and 33,250 restricted stock units to seven new non-executive employees under the Avidity Biosciences, Inc.

Neurocrine Biosciences, Inc. announced the publication of data from a post hoc analysis of the Phase 3 KINECT®-4 study of INGREZZA® capsules in the Journal of Clinical Psychopharmacology.

YS Biopharma Co., Ltd., a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, announced the results of its extraordinary general meeting held on May 21, 2024 in Hong Kong.

Atrion Corporation announced that its Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Next Gen Diagnostics and a team at Vanderbilt University Medical Center announced the results of a study reporting that comparison of the whole genome sequence of bacterial pathogens obtained from surveillance of infants in a neonatal intensive care unit revealed substantial transmission of infection not detected by conventional infection control procedures.

The realm of cancer treatment has progressed remarkably over the preceding decennium with the advent of multiple novel treatments that involves the combinations of antibodies for the treatment of different types of cancer across the globe

ACG Engineering, a division of ACG, the world’s only integrated pharmaceutical solutions and manufacturing company

Genmab A/S announced that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates s and ADC technologies for the treatment of cancers in an all-cash transaction of USD 1.8 billion.

PurMinds NeuroPharma (“PurMinds™" or the “Company”), a clinical-stage neuroscience company focused on advancing a robust pipeline of small molecules, psychedelic compounds, and other modalities for the treatment of neurological and neurodegenerative disorders